Job Description: Req #: 1901110
Location: Seattle, Washington, United States
Job Category: Research and Early Development
Work Location: 400 Dexter Ave N. 98109
Organization: Translational Medicine
Employee Status: Full-time
Job Type: Regular
The candidate will develop and execute in vivo and in vitro studies to support the development of T cell therapies and immune oncology drugs. Successful candidates will have a strong scientific track-record in the implementation and optimization of tumor and/or immune response models in mice coupled with a broad range of experience in vitro cell-based assay techniques, using both human and mouse immune and tumor cells. A demonstrated ability to independently design and execute experimental studies to meet project goals is required.
Qualifications and Education Requirements
Bachelor's degree in a scientific discipline with at least 6 years of immunology/oncology work experience, or Master's degree with at least 4 years of experience.
Proficiency in the care and handling procedures for immune-competent and immune-deficient murine tumor models and adoptive cell transfer models including techniques such as i.v. and s.c. injections
Expertise in multi-parameter flow cytometry, immune cell functional assays, and knowledge of cellular immunology/immuno-oncology
Expertise in conducting in vitro / ex vivo cell-based assays using primary human and mouse cells
Demonstrated independence in experimental design, data analysis and interpretation
Ability to work in a high paced team environment, meet deadlines, & prioritize work on multiple projects
Experience with IACUC protocol development and review
Experience with tumor models including syngeneic and xenograft models employing systemic, sub-cutaneous and orthotopic approaches and xenogeneic adoptive cellular transfer models
Experience with bioluminescent imaging technologies such as IVIS
Track record of successful internal and external scientific collaborations
Strong verbal and written skills
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
"At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients."
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.